Nicodrops, Inc. was incorporated for the purpose of bringing to market a unique, drug free line of lozenge products designed to help people who wish to stop smoking. The Company has developed its smoking cessation product in consultation with certified research herbalists over a ten-year period. With the completion of the product development, Nicodrops is now positioned to capitalize on the research and development activities by introducing their products to the market place.
LA MESA, Calif.--(BUSINESS WIRE)--Sept. 20, 2004--Nicodrops, Inc. (PINK SHEETS:NCDP) announces that the Company has commenced trading on the OTCBB (Pink Sheet) under Symbol (NCDP). Nicodrops is moving into the public marketplace to aggressively pursue a significant market share of the global smoking cessation market with the First Non Nicotine, Drug-Free product.
The Product
Nicodrops, Inc. is a unique, non-nicotine based product designed to assist people who wish to stop smoking.
Unlike its competitors, the product is drug free, faster acting and is less expensive.
The line of drug free smoking cessation products has been developed through a joint effort by National Group, National Healthcare Manufacturing Group, Mr. Christopher Calpito (Nicodrops CEO) and the Jamshidi Family.
The product has been in development since 1994. National Group has embarked on an extensive program to research various natural herbal products that ultimately culminated the Nicodrops product line.
LA MESA, Calif.--(BUSINESS WIRE)--Sept. 23, 2004--Nicodrops, Inc. (NCDP) today announced that it has formally received approval from the European Community (EC) to allow the company to distribute its proprietary products in the following 15 countries; UK, Ireland, Spain, Portugal, France, Germany, Italy, Greece, Belgium, Norway, Sweden, Denmark, Finland, Switzerland, and the Netherlands.
(4) Decreased skin temperature (5) Impact on muscle function and tone. (6) Skin redness, swelling, rash
(7) Nausea, vomiting, dizziness, weakness.
Price calculations: Nicodrops recommended usage (check program page), $59.70 (80 pieces). Nicorette 24 pieces/daily for 12 weeks, $50(108 piece starter kit)/5days, $70(refill 168 pieces)/each 8 days after. Commit Lozenge $554 12 (as of 1/27/04 per Drugstore.com) weeks 1 Lozenge every, 1-2 hrs 1-6 weeks, 2-4 hrs 7-9 weeks, 4-8 hrs 9-12th week. Nicoderm CQ 1 patch/daily for 10 weeks, $46(14 patches starter kit), $46(14 patch refill) 4 refills. Side Effects listed on the internet and medical studies for Nicotine and patch delivery system and on competitors own webpages. The FDA has approved herbs for use in food products. Herbal effects not listed are numerous and generally healthy. Persons should consult their physician before using Nicodrops or any smoking cessation program. - ALL RETAIL PRICES SHOWN ARE FOR USA SALES ONLY
Competing Products Comparison
Nicorette contains nicotine
Nicoderm contains nicotine
Both use nicotine to reduce the nicotine dependency and both could have adverse side afffects in certain individuals
(see chart below)
Nicodrops' product is the only product in the market that does not have any known side effects.
"We are excited about the opportunity before us. While our competitors continue to use nicotine in their products, our lozenges offer a much safer and effective alternative as well as being less expensive"
Christopher Calpito, President and Chief Executive Officer of Nicodrops, Inc
LA MESA, Calif.--(BUSINESS WIRE)--Sept. 28, 2004--Nicodrops, Inc. today announced that its Sugar Free
Lozenge is now in production.
Alternative Drug-Free Product (no nicotine)
Worldwide Market Potential (all smokers wanting to quit)
Easy Product To Use (lozenges)
Priced 74% to as much as 92% Cheaper Then The Competition
European Community Approval in 15 Countries
Product Now In Production
NCDP STOCK GOES PUBLIC 9-20-2004
GROUND FLOOR OPPORTUNITY
The Market
The Atlanta based Center for Disease Control estimates that 70 million or 24% of the entire population of the US are smokers. This translates into a market estimated at $700 Million annually in the United States alone.
Projecting this on to the Company's global target markets results in a population of approximately
250 million people with a dollar value of $2.5 Billion.
Alliances with major retailers are expected in the months ahead.
